Investment Thesis
IDEAYA is an early-stage pharmaceutical company with explosive revenue growth (3024% YoY) and a fortress balance sheet ($157.5M cash, zero debt) providing 2+ years of runway, but current fundamentals are deeply unprofitable with -$108.5M operating losses against minimal $6.6M revenue. Improving loss metrics YoY suggest progress, but path to profitability remains uncertain without visibility into pipeline success.
Strengths
- Exceptional revenue growth momentum of 3024% YoY indicating recent commercialization traction
- Fortress balance sheet with $1.0B assets, $157.5M cash, zero long-term debt eliminates near-term solvency risk
- Improving unit economics with 62% YoY reduction in diluted EPS losses demonstrates operational progress
- Excellent liquidity (10.74x current ratio) provides multi-year operational runway without external funding pressure
Risks
- Massive operating losses ($108.5M) against minimal revenue ($6.6M) reveal unsustainable cash burn model
- Catastrophic operating/net margins (-1654%/-1502%) reflect pre-commercial stage with heavy R&D and regulatory expenses
- Approximately 2 years of cash runway at $75M annual burn rate dependent on achieving profitability or capital raises
- Early-stage pharmaceutical company faces inherent high clinical and regulatory failure risk across pipeline
- Minimal insider activity (1 Form 4 filing in 90 days) suggests limited insider confidence or ownership
Key Metrics to Watch
- Revenue growth sustainability and path to $50M+ quarterly revenue
- Operating cash burn trajectory and timeline to cash flow breakeven
- Clinical pipeline progression, regulatory milestones, and commercial partnership announcements
- Cash runway extension through partnerships, milestone payments, or equity capital raises
Financial Metrics
Revenue
6.6M
Net Income
-98.5M
EPS (Diluted)
$-1.11
Free Cash Flow
-76.1M
Total Assets
1.0B
Cash
157.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,654.6%
Net Margin
-1,502.1%
ROE
-10.5%
ROA
-9.6%
FCF Margin
-1,160.6%
Balance Sheet & Liquidity
Current Ratio
10.74x
Quick Ratio
10.74x
Debt/Equity
0.00x
Debt/Assets
9.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T09:19:14.215154 |
Data as of: 2026-03-31 |
Powered by Claude AI